Orfenix

Orfenix operates as a venture builder with a distinctive model: we identify promising scientific ideas from leading principal investigators (PIs) and build dedicated ventures around them, advancing molecules to the market through impact capital funding. This model ensures a patient-first approach, rigorous development standards, and a lean, focused structure for each venture.

We currently highlight the following ventures as key examples of our technological and scientific value:

Patient One – Developing a novel formulation of Cysteamine for the treatment of Cystinosis, a rare lysosomal storage disorder.

GuanaRep – Developing a new therapeutic product targeting Vanishing White Matter (VWM) disease, a rare and devastating neurological condition.

Ectocalix – Developing Etidronate for the treatment of ectopic calcification disorders, specifically Pseudoxanthoma Elasticum (PXE) and Primary (Familial) Brain Calcification (P(F)BC).

Orfenix welcomes collaboration both at the group level, leveraging our venture-building expertise and impact capital model, and at the individual venture level, where specific scientific, clinical, or commercial partnerships can be explored with Patient One, GuanaRep, and Ectocalix respectively.